« Return to News | Drug Sponsors

Linden Capital Partners to acquire SeraCare for $82 million

Monday, February 13, 2012 03:08 PM

SeraCare Life Sciences, a global life sciences company, has agreed to be acquired by an affiliate of Linden Capital Partners, a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries.

Holders of outstanding shares of common stock of SeraCare will receive $4 per share, representing a 25% premium to the 30-day volume-weighted average stock price. SeraCare's board of directors unanimously approved the agreement.

“Linden is a natural strategic fit for SeraCare with a proven record of operating successful companies in the healthcare and life sciences sectors,” said Greg Gould, interim president, CEO and CFO. “Linden's acquisition of SeraCare recognizes our accomplishments and translates them into significant value for our shareholders.”

"SeraCare's product offerings, services and strong customer base provide an attractive foundation on which to compete and grow in the global high-growth markets of human diagnostics and therapeutics research and development," said Fran Lunger, a Linden Operating Partner and former CEO of Millipore.

If the merger is approved by shareholders, the transaction is expected to close in the second quarter of 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.